TY - JOUR
T1 - Photobiological neuromodulation of resting-state eeg and steady-state visual-evoked potentials by 40 hz violet light optical stimulation in healthy individuals
AU - Noda, Yoshihiro
AU - Takano, Mayuko
AU - Hayano, Motoshi
AU - Li, Xuemei
AU - Wada, Masataka
AU - Nakajima, Shinichiro
AU - Mimura, Masaru
AU - Kondo, Shinichiro
AU - Tsubota, Kazuo
N1 - Funding Information:
Acknowledgments: We would like to thank all the participants in this study and the research assistants who helped with the experiments. We would like to thank Tatsumi Furukawa and Makoto Sawano of Miyuki Giken Co., Ltd. (Tokyo, Japan) for their full support in setting up the experimental system for light stimulation. Y.N. has received a Grant-in-Aid for Young Scientists (18K15375) and a Grant-in-Aid for Scientific Research (B) (21H02813) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED (Tokyo, Japan) and Inter Reha Co., Ltd.(Tokyo, Japan) Y.N. also receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker’s honoraria from Dainippon Sumitomo Pharma, MOCHIDA PHARMACEUTICAL CO., LTD. (Tokyo, Japan), and Yoshitomiyakuhin Corporation within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc. (Farum, Denmark), Inter Reha Co., Ltd., BrainBox Ltd. (Cardiff, United Kingdom), and Miyuki Giken Co., Ltd. M.H. has received a Grant-in-Aid for Young Scientists (19K16619) and a Grant-in-Aid for Scientific Research on Innovative Areas (19H05269). S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees or speaker’s honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. M.M. received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin.
Funding Information:
We would like to thank all the participants in this study and the research assistants who helped with the experiments. We would like to thank Tatsumi Furukawa and Makoto Sawano of Miyuki Giken Co., Ltd. (Tokyo, Japan) for their full support in setting up the experimental system for light stimulation. Y.N. has received a Grant-in-Aid for Young Scientists (18K15375) and a Grant-in-Aid for Scientific Research (B) (21H02813) from the Japan Society for the Promotion of Science (JSPS), research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED (Tokyo, Japan) and Inter Reha Co., Ltd.(Tokyo, Japan) Y.N. also receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program. Y.N. has received speaker?s honoraria from Dainippon Sumitomo Pharma, MOCHIDA PHARMACEUTICAL CO., LTD. (Tokyo, Japan), and Yoshitomiyakuhin Corporation within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc. (Farum, Denmark), Inter Reha Co., Ltd., BrainBox Ltd. (Cardiff, United Kingdom), and Miyuki Giken Co., Ltd. M.H. has received a Grant-in-Aid for Young Scientists (19K16619) and a Grant-in-Aid for Scientific Research on Innovative Areas (19H05269). S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees or speaker?s honoraria from Dainippon Sumitomo Pharma, MeijiSeika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. M.M. received grants and/or speaker?s honoraria from Asahi Kasei Pharma, Astellas Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, Merck Sharp and Dohme, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Yoshitomi Yakuhin.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/6
Y1 - 2021/6
N2 - Photobiological neuromodulation and its clinical application has been investigated in recent years. The response of the gamma-oscillation to human visual stimuli is known to be both burst and resonant in nature, and the coupling between alpha and gamma oscillations may play a functional role in visual processing. To date, there is no study that examined the effects of gamma-frequency violet light (VL) stimulation on human electroencephalography (EEG). In this study, we investigated the neurophysiological changes induced by light stimulation using EEG. The purpose of this study was to evaluate the specific effects of 40 Hz gamma-frequency VL stimulation on EEG activity by comparing the effects of white light (WL) with the same condition. Twenty healthy participants (10 females: 37.5 ± 14.3 years; 10 males: 38.0 ± 13.3 years) participated in this study and the following results were observed. First, when compared with the power spectrum density (PSD) of baseline EEG, 40 Hz-WL induced significant increase of PSD in theta band. Second, compared the PSDs between EEG with 40 Hz-VL and EEG with 40 Hz-WL, 40 Hz-VL induced significantly lower enhancement in delta and theta bands than 40 Hz-WL. Third, when focused on the occipital area, negative peak of VEP with 40 Hz-VL was smaller than that of 40 Hz-WL. Fourth, 40 Hz-VL induced an increase of alpha-gamma coupling during the VEP at the F5 electrode site as well as post-EEG at the C4 electrode site, compared with baseline EEG. Thus, the present study suggested that 40 Hz-VL stimulation may induce unique photobiological neuromodulations on human EEG activity.
AB - Photobiological neuromodulation and its clinical application has been investigated in recent years. The response of the gamma-oscillation to human visual stimuli is known to be both burst and resonant in nature, and the coupling between alpha and gamma oscillations may play a functional role in visual processing. To date, there is no study that examined the effects of gamma-frequency violet light (VL) stimulation on human electroencephalography (EEG). In this study, we investigated the neurophysiological changes induced by light stimulation using EEG. The purpose of this study was to evaluate the specific effects of 40 Hz gamma-frequency VL stimulation on EEG activity by comparing the effects of white light (WL) with the same condition. Twenty healthy participants (10 females: 37.5 ± 14.3 years; 10 males: 38.0 ± 13.3 years) participated in this study and the following results were observed. First, when compared with the power spectrum density (PSD) of baseline EEG, 40 Hz-WL induced significant increase of PSD in theta band. Second, compared the PSDs between EEG with 40 Hz-VL and EEG with 40 Hz-WL, 40 Hz-VL induced significantly lower enhancement in delta and theta bands than 40 Hz-WL. Third, when focused on the occipital area, negative peak of VEP with 40 Hz-VL was smaller than that of 40 Hz-WL. Fourth, 40 Hz-VL induced an increase of alpha-gamma coupling during the VEP at the F5 electrode site as well as post-EEG at the C4 electrode site, compared with baseline EEG. Thus, the present study suggested that 40 Hz-VL stimulation may induce unique photobiological neuromodulations on human EEG activity.
KW - Alpha-phase and gammaamplitude coupling
KW - Photobiological neuromodulation
KW - Resting-state electroencephalography (EEG)
KW - Steady-state gamma-frequency stimulation
KW - Violet light
KW - Visual-evoked potential
UR - http://www.scopus.com/inward/record.url?scp=85108802589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108802589&partnerID=8YFLogxK
U2 - 10.3390/jpm11060557
DO - 10.3390/jpm11060557
M3 - Article
AN - SCOPUS:85108802589
SN - 2075-4426
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 6
M1 - 557
ER -